Search research articles
Contact Us
Filters
Showing results (21-30 of 28) with videos related to
Page
of 3
Sort By:
You have reached the last page of results.
This site can display upto 28 results.
Frontiers in Pharmacology
|
February 20, 2024
Concomitant inhibition of PI3K/mTOR signaling pathways boosts antiproliferative effects of lanreotide in bronchopulmonary neuroendocrine tumor cells
Claus von Hessert-Vaudoncourt, Sara Lelek, Christina Geisler, et al.
Plos One
|
August 12, 2017
The selective PI3Kα inhibitor BYL719 as a novel therapeutic option for neuroendocrine tumors: Results from multiple cell line models
Svenja Nölting, Jakob Rentsch, Helma Freitag, et al.
Neuroendocrinology
|
September 15, 2017
Mechanisms of Targeting the MDM2-p53-FOXM1 Axis in Well-Differentiated Intestinal Neuroendocrine Tumors
Franziska Briest, Irina Grass, Dagmar Sedding, et al.
Nature Communications
|
August 30, 2022
A prospective observational study of post-COVID-19 chronic fatigue syndrome following the first pandemic wave in Germany and biomarkers associated with symptom severity
Claudia Kedor, Helma Freitag, Lil Meyer-Arndt, et al.
Nature Communications
|
October 12, 2022
Author Correction: A prospective observational study of post-COVID-19 chronic fatigue syndrome following the first pandemic wave in Germany and biomarkers associated with symptom severity
Claudia Kedor, Helma Freitag, Lil Meyer-Arndt, et al.
Oncotarget
|
December 13, 2017
Proteasome inhibitor bortezomib enhances the effect of standard chemotherapy in small cell lung cancer
Sanaz Taromi, Florentine Lewens, Ruza Arsenic, et al.
Journal of Clinical Medicine
|
June 19, 2024
The German Multicenter Registry for ME/CFS (MECFS-R)
Hannah Hieber, Rafael Pricoco, Katrin Gerrer, et al.
Frontiers in Immunology
|
October 14, 2022
Dysregulated autoantibodies targeting vaso- and immunoregulatory receptors in Post COVID Syndrome correlate with symptom severity
Franziska Sotzny, Igor Salerno Filgueiras, Claudia Kedor, et al.
Page
of 3
Search research articles
Search
Showing results (21-30 of 28) with videos related to
Sort By:
Page
of 3
You have reached the last page of results.
This site can display upto 28 results.
Frontiers in Pharmacology
|
February 20, 2024
Concomitant inhibition of PI3K/mTOR signaling pathways boosts antiproliferative effects of lanreotide in bronchopulmonary neuroendocrine tumor cells
Claus von Hessert-Vaudoncourt, Sara Lelek, Christina Geisler, et al.
Plos One
|
August 12, 2017
The selective PI3Kα inhibitor BYL719 as a novel therapeutic option for neuroendocrine tumors: Results from multiple cell line models
Svenja Nölting, Jakob Rentsch, Helma Freitag, et al.
Neuroendocrinology
|
September 15, 2017
Mechanisms of Targeting the MDM2-p53-FOXM1 Axis in Well-Differentiated Intestinal Neuroendocrine Tumors
Franziska Briest, Irina Grass, Dagmar Sedding, et al.
Nature Communications
|
August 30, 2022
A prospective observational study of post-COVID-19 chronic fatigue syndrome following the first pandemic wave in Germany and biomarkers associated with symptom severity
Claudia Kedor, Helma Freitag, Lil Meyer-Arndt, et al.
Nature Communications
|
October 12, 2022
Author Correction: A prospective observational study of post-COVID-19 chronic fatigue syndrome following the first pandemic wave in Germany and biomarkers associated with symptom severity
Claudia Kedor, Helma Freitag, Lil Meyer-Arndt, et al.
Oncotarget
|
December 13, 2017
Proteasome inhibitor bortezomib enhances the effect of standard chemotherapy in small cell lung cancer
Sanaz Taromi, Florentine Lewens, Ruza Arsenic, et al.
Journal of Clinical Medicine
|
June 19, 2024
The German Multicenter Registry for ME/CFS (MECFS-R)
Hannah Hieber, Rafael Pricoco, Katrin Gerrer, et al.
Frontiers in Immunology
|
October 14, 2022
Dysregulated autoantibodies targeting vaso- and immunoregulatory receptors in Post COVID Syndrome correlate with symptom severity
Franziska Sotzny, Igor Salerno Filgueiras, Claudia Kedor, et al.
Page
of 3